Unusual 11 Mid-Day Movers 05/11: (ARNA) (RPRX) (GWAY) Higher; (ADY) (AMOT) (ASYS) Lower
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) 71.9% HIGHER; Arena and Eisai Inc. announced that the US FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4, with one abstention, that the available data demonstrate that the potential benefits of lorcaserin outweigh the potential risks when used long-term in a population of overweight and obese individuals. Lorcaserin is an investigational drug candidate intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (BMI greater than or equal to 30) or patients who are overweight (BMI greater than or equal to 27) and have at least one weight-related co-morbid condition.
Repros Therapeutics (Nasdaq: RPRX) 33.8% HIGHER; stock is continuing higher today following news the company and the FDA reached an agreement on the Androxal registration program and the resulting 31.5% rise yesterday.
Greenway Medical Technologies (NYSE: GWAY) 21.5% HIGHER; reported Q3 EPS of $0.08, $0.04 better than the analyst estimate of $0.04. Revenue for the quarter came in at $32.9 million versus the consensus estimate of $28.54 million.
Feihe International (NYSE: ADY) 21.4% LOWER; traders are taking some profits following a 49 percent rise yesterday on the heels of strong Q1 results.
Monster Worldwide, Inc. (NYSE: MWW) 20.4% HIGHER; reports out that the company is drawing takeover interest from LinkedIn and private equity firm Silver Lake, among others.
Allied Motion Technologies, Inc. (Nasdaq: AMOT) 20.1% LOWER; reported Q1 EPS of $0.14, versus $0.14 reported last year. Revenue for the quarter came in at $26.8 million, versus $26.72 million reported last year.
Keryx Biopharma (Nasdaq: KERX) 20.0% HIGHER; the stock is continuing higher following a 13 percent yesterday amid several upgrades.
Amtech Systems (Nasdaq: ASYS) 18.8% LOWER; reported Q2 EPS of ($0.54), $0.32 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $21.55 million. Sees FY2012 revenue of $18-$20 million, versus the consensus of $27 million.
Orexigen (Nasdaq: OREX) 17.0% HIGHER; Arena won FDA panel backing for its lorcaserin drug candidate.
Kemet (NYSE: KEM) 16.5% LOWER; BofA/Merrill Lynch downgraded the stock from Buy to Underperform.
Roundys (NYSE: RNDY) 15.5% LOWER; reported Q1 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $938.2 million versus the consensus estimate of $929.4 million.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Repros Therapeutics (Nasdaq: RPRX) 33.8% HIGHER; stock is continuing higher today following news the company and the FDA reached an agreement on the Androxal registration program and the resulting 31.5% rise yesterday.
Greenway Medical Technologies (NYSE: GWAY) 21.5% HIGHER; reported Q3 EPS of $0.08, $0.04 better than the analyst estimate of $0.04. Revenue for the quarter came in at $32.9 million versus the consensus estimate of $28.54 million.
Feihe International (NYSE: ADY) 21.4% LOWER; traders are taking some profits following a 49 percent rise yesterday on the heels of strong Q1 results.
Monster Worldwide, Inc. (NYSE: MWW) 20.4% HIGHER; reports out that the company is drawing takeover interest from LinkedIn and private equity firm Silver Lake, among others.
Allied Motion Technologies, Inc. (Nasdaq: AMOT) 20.1% LOWER; reported Q1 EPS of $0.14, versus $0.14 reported last year. Revenue for the quarter came in at $26.8 million, versus $26.72 million reported last year.
Keryx Biopharma (Nasdaq: KERX) 20.0% HIGHER; the stock is continuing higher following a 13 percent yesterday amid several upgrades.
Amtech Systems (Nasdaq: ASYS) 18.8% LOWER; reported Q2 EPS of ($0.54), $0.32 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $21.55 million. Sees FY2012 revenue of $18-$20 million, versus the consensus of $27 million.
Orexigen (Nasdaq: OREX) 17.0% HIGHER; Arena won FDA panel backing for its lorcaserin drug candidate.
Kemet (NYSE: KEM) 16.5% LOWER; BofA/Merrill Lynch downgraded the stock from Buy to Underperform.
Roundys (NYSE: RNDY) 15.5% LOWER; reported Q1 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $938.2 million versus the consensus estimate of $929.4 million.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FirstEnergy Corp. (FE) PT Raised to $35 at BofA Securities
- Zillow Group (ZG) PT Lowered to $53 at BofA Securities
- Dominion Resources, Inc. (D) PT Raised to $43 at BofA Securities
Create E-mail Alert Related Categories
Special ReportsRelated Entities
American Technology Research, Unusual 11 Mid-Day MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
